{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:05:25Z","timestamp":1778771125579,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40261-026-01533-3","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:39:04Z","timestamp":1771933144000},"page":"447-453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study"],"prefix":"10.1007","volume":"46","author":[{"given":"Michela","family":"Starace","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2931-767X","authenticated-orcid":false,"given":"Francesca","family":"Pampaloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Quadrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Olivoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephano","family":"Cedirian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Rapparini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"7","key":"1533_CR1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/ijd.13866","volume":"57","author":"K Chelidze","year":"2018","unstructured":"Chelidze K, Lipner SR. Nail changes in alopecia areata: an update and review. Int J Dermatol. 2018;57(7):776\u201383. https:\/\/doi.org\/10.1111\/ijd.13866.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1533_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/bjd\/ljae058","volume":"191","author":"JJ Jeon","year":"2024","unstructured":"Jeon JJ, Jung SW, Kim YH, Parisi R, Lee JY, Kim MH, et al. Global, regional and national epidemiology of alopecia areata: a systematic review and modelling study. Br J Dermatol. 2024;191(3):325\u201335. https:\/\/doi.org\/10.1093\/bjd\/ljae058.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1533_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1468-3083.2008.02830.x","volume":"23","author":"E Kasumagic-Halilovic","year":"2009","unstructured":"Kasumagic-Halilovic E, Prohic A. Nail changes in alopecia areata: frequency and clinical presentation. J Eur Acad Dermatol Venereol. 2009;23(2):240\u20131. https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02830.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1533_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.2340\/00015555-2810","volume":"98","author":"YBM Roest","year":"2018","unstructured":"Roest YBM, van Middendorp HT, Evers AWM, van de Kerkhof PCM, Pasch MC. Nail involvement in alopecia areata: a questionnaire-based survey on clinical signs, impact on quality of life and review of the literature. Acta Derm Venereol. 2018;98(2):212\u20137. https:\/\/doi.org\/10.2340\/00015555-2810.","journal-title":"Acta Derm Venereol"},{"key":"1533_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000131412","volume":"10","author":"T Ito","year":"2008","unstructured":"Ito T, Meyer KC, Ito N, Paus R. Immune privilege and the skin. Curr Dir Autoimmun. 2008;10:27\u201352. https:\/\/doi.org\/10.1159\/000131412.","journal-title":"Curr Dir Autoimmun"},{"issue":"2","key":"1533_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1525-1470.1994.tb00562.x","volume":"11","author":"A Tosti","year":"1994","unstructured":"Tosti A, Morelli R, Bardazzi F, Peluso AM. Prevalence of nail abnormalities in children with alopecia areata. Pediatr Dermatol. 1994;11(2):112\u20135. https:\/\/doi.org\/10.1111\/j.1525-1470.1994.tb00562.x.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"1533_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/archderm.1980.01640290083019","volume":"116","author":"RT Horn Jr","year":"1980","unstructured":"Horn RT Jr, Odom RB. Twenty-nail dystrophy of alopecia areata. Arch Dermatol. 1980;116(5):573\u20134.","journal-title":"Arch Dermatol"},{"issue":"11","key":"1533_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13113292","volume":"13","author":"C Pelzer","year":"2024","unstructured":"Pelzer C, Iorizzo M. Alopecia areata of the nails: diagnosis and management. J Clin Med. 2024;13(11):3292. https:\/\/doi.org\/10.3390\/jcm13113292.","journal-title":"J Clin Med"},{"issue":"5","key":"1533_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2165\/11592120-000000000-00000","volume":"12","author":"A Reich","year":"2011","unstructured":"Reich A, Szepietowski JC. Health-related quality of life in patients with nail disorders. Am J Clin Dermatol. 2011;12(5):313\u201320. https:\/\/doi.org\/10.2165\/11592120-000000000-00000.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1533_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jaad.2009.10.032","volume":"62","author":"A Alkhalifah","year":"2010","unstructured":"Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62(2):177\u201388. https:\/\/doi.org\/10.1016\/j.jaad.2009.10.032.","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"1533_CR11","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"10387","key":"1533_CR12","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023;401(10387):1518\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(23)00222-2.","journal-title":"Lancet"},{"issue":"9","key":"1533_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-023-01873-w","volume":"83","author":"E Freitas","year":"2023","unstructured":"Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the treatment of alopecia areata. Drugs. 2023;83(9):761\u201370. https:\/\/doi.org\/10.1007\/s40265-023-01873-w.","journal-title":"Drugs"},{"issue":"1","key":"1533_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.23736\/S2784-8671.23.07778-2","volume":"159","author":"A Rossi","year":"2024","unstructured":"Rossi A, Caro G, Starace M, Piraccini BM, Italian Study Group on Cutaneous Adnexal Disease of the Italian Society of Dermatology and Sexual Transmitted diseases (SIDeMaST). Integration to the \u201cItalian guidelines in diagnosis and treatment of alopecia areata.\u201d Ital J Dermatol Venerol. 2024;159(1):78\u20139. https:\/\/doi.org\/10.23736\/S2784-8671.23.07778-2.","journal-title":"Ital J Dermatol Venerol"},{"issue":"6","key":"1533_CR15","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/jdv.20312","volume":"39","author":"BM Piraccini","year":"2025","unstructured":"Piraccini BM, Pampaloni F, Cedirian S, Quadrelli F, Bruni F, Rapparini L, et al. Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: a 24-week Italian study. J Eur Acad Dermatol Venereol. 2025;39(6):1143\u201351. https:\/\/doi.org\/10.1111\/jdv.20312.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1533_CR16","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.jaad.2020.02.056","volume":"83","author":"M Iorizzo","year":"2020","unstructured":"Iorizzo M, Tosti A, Starace M, Baran R, Daniel 3rdCR, Di Chiacchio N, et al. Isolated nail lichen planus: an expert consensus on treatment of the classical form. J Am Acad Dermatol. 2020;83(6):1717\u201323. https:\/\/doi.org\/10.1016\/j.jaad.2020.02.056.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1533_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1159\/000450848","volume":"8","author":"SB Ferreira","year":"2016","unstructured":"Ferreira SB, Scheinberg M, Steiner D, Steiner T, Bedin GL, Ferreira RB. Remarkable improvement of nail changes in alopecia areata universalis with 10 months of treatment with tofacitinib: a case report. Case Rep Dermatol. 2016;8(3):262\u20136. https:\/\/doi.org\/10.1159\/000450848.","journal-title":"Case Rep Dermatol"},{"issue":"8","key":"1533_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1080\/09546634.2018.1466024","volume":"29","author":"JS Lee","year":"2018","unstructured":"Lee JS, Huh CH, Kwon O, Yoon HS, Cho S, Park HS. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib. J Dermatolog Treat. 2018;29(8):819\u201322.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1533_CR19","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/jocd.16049","volume":"23","author":"A Asilian","year":"2024","unstructured":"Asilian A, Mohammadian P, Shahmoradi Z. Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran. J Cosmet Dermatol. 2024;23(3):886\u201390.","journal-title":"J Cosmet Dermatol"},{"issue":"2024","key":"1533_CR20","first-page":"8879884","volume":"31","author":"A Wittmer","year":"2024","unstructured":"Wittmer A, De Jong K, Bolish L, Finklea L. Therapeutic response of alopecia areata-associated nail changes to baricitinib. Case Rep Dermatol Med. 2024;31(2024):8879884.","journal-title":"Case Rep Dermatol Med."},{"issue":"8","key":"1533_CR21","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/ijd.17137","volume":"63","author":"P R\u00f3zsa","year":"2024","unstructured":"R\u00f3zsa P, Degovics D, Balt\u00e1s E, Gyulai R, Kem\u00e9ny L. Successful treatment of alopecia areata-associated trachyonychia with baricitinib. Int J Dermatol. 2024;63(8):1089\u201390.","journal-title":"Int J Dermatol"},{"issue":"5","key":"1533_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40257-020-00545-9","volume":"21","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, et al. Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata. Am J Clin Dermatol. 2020;21(5):725\u201332. https:\/\/doi.org\/10.1007\/s40257-020-00545-9.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1533_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/ced\/llae320","volume":"50","author":"E Darchini-Maragheh","year":"2025","unstructured":"Darchini-Maragheh E, Moussa A, Rees H, Jones L, Bokhari L, Sinclair R. Assessment of clinician-reported outcome measures for alopecia areata: a systematic scoping review. Clin Exp Dermatol. 2025;50(2):267\u201378. https:\/\/doi.org\/10.1093\/ced\/llae320.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1533_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jdermsci.2023.09.008","volume":"112","author":"T Dainichi","year":"2023","unstructured":"Dainichi T, Iwata M, Kaku Y. Alopecia areata: what\u2019s new in the epidemiology, comorbidities, and pathogenesis? J Dermatol Sci. 2023;112(3):120\u20137. https:\/\/doi.org\/10.1016\/j.jdermsci.2023.09.008.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"1533_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","volume":"61","author":"C Zhou","year":"2021","unstructured":"Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021;61(3):403\u201323. https:\/\/doi.org\/10.1007\/s12016-021-08883-0.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"1533_CR26","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043\u20139. https:\/\/doi.org\/10.1038\/nm.3645.","journal-title":"Nat Med"},{"issue":"5 Suppl.","key":"1533_CR27","doi-asserted-by":"publisher","first-page":"27S","DOI":"10.1038\/jid.1995.47","volume":"104","author":"A Tosti","year":"1995","unstructured":"Tosti A, Bardazzi F, Piraccini BM, Fanti PA, Cameli N, Pileri S. Is trachyonychia, a variety of alopecia areata, limited to the nails? J Invest Dermatol. 1995;104(5 Suppl.):27S-S28. https:\/\/doi.org\/10.1038\/jid.1995.47.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1533_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10238-020-00673-w","volume":"21","author":"A Sterkens","year":"2021","unstructured":"Sterkens A, Lambert J, Bervoets A. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. Clin Exp Med. 2021;21(2):215\u201330. https:\/\/doi.org\/10.1007\/s10238-020-00673-w.","journal-title":"Clin Exp Med"},{"issue":"4","key":"1533_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40257-025-00946-8","volume":"26","author":"M Iorizzo","year":"2025","unstructured":"Iorizzo M, Sechi A, Neubauer ZJK, Zhou M, Lipner SR. JAK inhibitors and inflammatory nail disorders: a systematic review of clinical outcomes and therapeutic potential. Am J Clin Dermatol. 2025;26(4):525\u201336.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1533_CR30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1001\/jamadermatol.2015.3772","volume":"152","author":"A Dhayalan","year":"2016","unstructured":"Dhayalan A, King BA. Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA Dermatol. 2016;152(4):492\u20133.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1533_CR31","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s10067-017-3574-0","volume":"36","author":"JA Jaller","year":"2017","unstructured":"Jaller JA, Jaller JJ, Jaller AM, Jaller-Char JJ, Ferreira SB, Ferreira R, et al. Recovery of nail dystrophy potential new therapeutic indication of tofacitinib. Clin Rheumatol. 2017;36(4):971\u20133.","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01533-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01533-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01533-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:35:30Z","timestamp":1773848130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01533-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1533"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01533-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michela Starace, Francesca Pampaloni, Federico Quadrelli, Giulia Olivoni, Stephano Cedirian, Luca Rapparini, Francesca Bruni, and Bianca Maria Piraccini have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the local Institutional Review Board (Comitato Etico di Area Vasta Emilia Centro, CE-AVEC, protocol n\u00b0641\/2024).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The patients in this article have given written informed consent to participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The patients in this article have given written informed consent during the enrollment phase to the publication of their case details.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data underlying this article will be shared on reasonable request to the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"BMP and MS conceptualized and designed the study. BMP, MS, and FP performed the data analysis, and wrote the initial draft of the manuscript. BMP, MS, and FP contributed to the data interpretation. FP, GO, and FQ performed the data collection. All authors provided critical revisions, and read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}